Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Nimbus Therapeutics is raising $125,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jeb Keiper played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nimbus Therapeutics
At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients.

To learn more about Nimbus Therapeutics, visit http://www.nimbustx.com/

Contact:
Jeb Keiper, Chief Executive Officer
857-999-2009
https://www.linkedin.com/in/jebkeiper/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved